Citigroup’s Genmab GMAB Stock Holding History

Citigroup’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100	Closed	-$3.78K	–	5628
2023 Q1	$3.78K	Buy	+100	New	+$3.84K	﹤0.01%	4999

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's GMAB Position: Q2 2026 in Review

Citigroup reduced its Genmab (GMAB) stake by 11% in Q2 2026, selling an estimated $90.7K and leaving 27,531 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #3647.

Citigroup first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $3.82M in Q4 2020. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Citigroup held 27,531 shares of Genmab worth $756K as of Q2 2026.
Citigroup sold 3,412 Genmab shares in Q2 2026, an estimated $90.7K.
Genmab made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3647 holding.
Citigroup first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
Citigroup's Genmab position peaked at $3.82M in Q4 2020.
291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.